Clinical Trial Update: Nivolumab With Ipilimumab in Subjects With Neuroendocrine Tumors [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating nivolumab with ipilimumab in neuroendocrine tumors (including carcinoid) has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Carcinoid Tumor
• Neuroendocrine Tumors

Drugs mentioned

• ipilimumab (ipilimumab)
• nivolumab (nivolumab)

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Conditions: Neuroendocrine Tumors, Carcinoid Tumor | Phase 2 | Status: TERMINATED | Results posted: 2024-01-09